# Special Issue

# Current State of Global African Swine Fever Vaccine Development

## Message from the Guest Editors

African swine fever virus (ASFV) is the etiological agent of African swine fever (ASF), a disease affecting both wild boar and domestic pigs. ASFV now represents one of the most important concerns for society, swine exploitation and the food industry worldwide. The virulence varies among the different ASFV strains, ranging from the acute infections with 100% mortality produced by highly virulent strains, to chronic infections presenting low or no mortality induced by attenuated strains. The molecular mechanisms leading to virulence are of great importance for understanding viral pathogenesis, being a direct component in the rational design of vaccines. In this regard, a key element differentiating attenuated from virulent strains is the different ability to control host IFN-I production. Most probably, no efficient and safe vaccines against ASF will be developed without a more complete understanding of the virus–host interaction, specifically, of the viral mechanisms used to evade the host's innate immune response.

## Guest Editors


Dr. Yolanda Revilla

Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Microbes in Health and Welfare Department, c/ Nicolás Cabrera, 1, 28049 Madrid, Spain

Dr. Daniel Pérez-Núñez

Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Microbes in Health and Welfare Department, c/ Nicolás Cabrera, 1, 28049 Madrid, Spain


## Deadline for manuscript submissions

closed (31 December 2022)


# Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/86755

*Vaccines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

# Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

# About the Journal

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

## Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI